Nestec S.a.

Societe Des Produits Nestle S.a.

Institut Curie

Dominique Brassart

Norbert Sprenger

Jean-Richard Neeser

Eduardo Schiffrin

Delphine Egli

Clemens Kunz

Florence Rochat

Alain Servin

Harriet Link

Olivier Mignot

Veronique Jaussan

Anne Donnet

Thomas Schweizer

Thierry Brun

Gyula Dekany

Sebastian Amigorena

Peter Erdmann

Kevin Burke Miller

Pierre Michetti

Andrea Schwarz

Olivier Jacques Lantz

A composition contains at least one fucosylated oligosaccharide, for use in preventing and/or treating a URT infection in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, ii) the infant or young child has at least one sibling, and iii) the infant or young child was born by C-section.

Compositions for use in the prevention or treatment of URT infections in infants or young children at risk

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in particular amounts, for use in preventing and/or treating infections and/or inflammations of the lower respiratory tract and/or of the ear in an infant or a young child.

Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide for use in preventing and/or treating constipation and/or in improving stool consistency/frequency in an infant or a young child.

Compositions for use in improving stool consistency or frequency in infants or young children

The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing allergies and/or treating allergies and/or reducing the occurrence or the risk of allergies in an infant or a young child born from a mother deficient in at least one fucosylated oligosaccharide(s) or fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s). The use of said composition in infant formula, milk fortifier or children's food is foreseen.

Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section

The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide and at least one N-acetylated oligosaccharide in a particular ratio, for use in preventing and/or treating gastrointestinal infections and/or gastrointestinal inflammations in an infant or a young child.

Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children

A method for the manufacture an infant formula or an infant nutritional product comprising mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2 with particular oligosaccharide profiles.

Nutritional products comprising human milk oligosaccharides and methods for manufacture thereof

The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing and/or treating URT infections in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s) ii) the infant or young child has at least one sibling iii) the infant or young child was born by C-section.

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

An enteral composition which contains a protein source, a lipid source, a carbohydrate source, and a fibre blend. The fibre blend contains inulin and fructo-oligosaccharides and has 45 to 55% by weight of the blend of soluble fibre and 45 to 55% by weight of the blend of insoluble fibre. The fibre blend may also contain pea inner fibres and pea outer envelope fibres.

Fiber blend for enteral composition

Nutritive composition based on fibers comprising at least a mixture of pea internal fibers, pea external envelope fibers and inulin.

Nutritive composition

Lactobacillus johnsonii strain CNCM I-1225 adheres to Caco-2 cells and inhibits adhesion thereto by enterovirulent and enteroinvasive pathogens.

Lactobacillus johnsonii CNCM I-1225

Stomach ulcers are treated by administering orally to a human in need thereof an anti-Helicobacter pylori effective amount of a composition containing, in combination with an ingestible support, a culture of Lactobacillus johnsonii strain CNCM I-1225 or a supernatant phase isolated from a culture of Lactobacillus johnsonii strain CNCM I-1225.

Treatment of stomach ulcers

Bifidobacterium breve CNCM I-1226, Bifidobacterium infantis CNCM I-227 and Bifidobacterium longum CNCM I-1228 adhere to and competitively exclude pathogenic bacteria from Caco-2 cells. The strains may be incorporated into yogurts, acidified milks and other food compositions.

Growing community of inventors

Chavannes-pres-Renens, Switzerland

Dominique Brassart